title: Administration of thymopentin to patients with phobic disorders improves depressed phagocytic functions.
abstract: Seven patients with phobic disorders were administered with a synthetic thymic extract, thymopentin (TP-5), in order to correct depressed polymorphonuclear cell (PMN) and monocyte phagocytosis and killing capacities. Subcutaneous administration (50 mg, three times weekly, for a period of 8 wks) of TP-5 resulted in a significant increase in phagocytic function with no change in the phagocytic capacity of PMN. These data support the concept that immunomodulators can achieve a correction of immune deficiencies associated with phobic disorders.
authors.affiliation: Istituto di Clinica Neurologica, II Facoltà di Medicina e Chirurgia, Università di Napoli, Italy.
authors.forename: V
authors.initials: V
authors.lastname: Covelli
authors.forename: I
authors.initials: I
authors.lastname: Munno
authors.forename: M
authors.initials: M
authors.lastname: Altamura
authors.forename: N M
authors.initials: NM
authors.lastname: Pellegrino
authors.forename: P
authors.initials: P
authors.lastname: Decandia
authors.forename: E
authors.initials: E
authors.lastname: Jirillo
mesh_terms: D000328:Adult; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D005260:Female; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000150:complications / Q000188:drug therapy; D066298:In Vitro Techniques; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects / Q000276:immunology; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology; D010586:Phagocytes / Q000187:drug effects* / Q000276:immunology; D010587:Phagocytosis / Q000187:drug effects; D010698:Phobic Disorders / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D016305:Thymopentin / Q000627:therapeutic use*
chemical_list: D016305:Thymopentin